CBP 307

Drug Profile

CBP 307

Alternative Names: CBP307

Latest Information Update: 18 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Suzhou Connect Biopharmaceuticals
  • Class Antipsoriatics
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 20 Nov 2014 CBP 307 is available for licensing in (excluding China) as of 06 Nov 2014. http://www.connectbiopharm.com/
  • 01 Nov 2014 Phase-I clinical trials in Autoimmune disorders (In volunteers) in Australia (PO)
  • 20 Oct 2014 Suzhou Connect Biopharmaceuticals plans a phase I trial for Autoimmune disorders (in volunteers) in Australia (NCT02280434)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top